Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastric fundus mucosal ablation plus intragastric botulinum toxin vs botulinum toxin alone for obesity
IRCT20230314057717N5Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of neuronox in obesity (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Weight loss. Started May 2026; status: completed.
02
Drugs
neuronox
03
Conditions
obesity
Beyond the preview
Go deeper on IRCT20230314057717N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230314057717N5.